📊 PTHS Key Takeaways
Is Pelthos Therapeutics Inc. (PTHS) a Good Investment?
Pelthos is a pre-commercial biopharmaceutical company with minimal revenue ($10.9M) and accelerating operating losses (operating margin -120%, net income declined 444.6% YoY). Negative free cash flow of -$13.3M annually against only $32M cash reserves leaves approximately 2-3 years of runway, creating material liquidity risk before achieving product commercialization.
Pelthos Therapeutics Inc. Key Strengths (PTHS)
- Zero long-term debt eliminates leverage and default risk
- Strong liquidity ratios (2.79x current, 1.86x quick) provide near-term operational flexibility
- Maintains $32M cash reserve providing runway for continued R&D operations
PTHS Stock Risks: Pelthos Therapeutics Inc. Investment Risks
- Severe and deteriorating profitability with operating losses exceeding revenue by 120%
- Net income declined 444.6% YoY indicating accelerating cash burn and worsening financial trajectory
- Limited cash runway of ~2-3 years at current burn rate creates existential liquidity risk without significant revenue growth or external capital
Key Metrics to Watch
- Quarterly revenue growth rate and path to product commercialization
- Monthly operating cash burn rate and updated runway analysis
- Clinical trial progress, regulatory milestones, and financing activities
Pelthos Therapeutics Inc. (PTHS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.79x current ratio provides a solid financial cushion.
PTHS Profit Margin, ROE & Profitability Analysis
PTHS vs Healthcare Sector: How Pelthos Therapeutics Inc. Compares
How Pelthos Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pelthos Therapeutics Inc. Stock Overvalued? PTHS Valuation Analysis 2026
Based on fundamental analysis, Pelthos Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pelthos Therapeutics Inc. Balance Sheet: PTHS Debt, Cash & Liquidity
PTHS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pelthos Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.27 indicates the company is currently unprofitable.
PTHS Revenue Growth, EPS Growth & YoY Performance
PTHS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$2.0M | $-3.09 |
| Q3 2025 | $294.0K | -$1.7M | $-2.93 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pelthos Therapeutics Inc. Dividends, Buybacks & Capital Allocation
PTHS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pelthos Therapeutics Inc. (CIK: 0001919246)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTHS
What is the AI rating for PTHS?
Pelthos Therapeutics Inc. (PTHS) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTHS's key strengths?
Claude: Zero long-term debt eliminates leverage and default risk. Strong liquidity ratios (2.79x current, 1.86x quick) provide near-term operational flexibility.
What are the risks of investing in PTHS?
Claude: Severe and deteriorating profitability with operating losses exceeding revenue by 120%. Net income declined 444.6% YoY indicating accelerating cash burn and worsening financial trajectory.
What is PTHS's revenue and growth?
Pelthos Therapeutics Inc. reported revenue of $10.9M.
Does PTHS pay dividends?
Pelthos Therapeutics Inc. does not currently pay dividends.
Where can I find PTHS SEC filings?
Official SEC filings for Pelthos Therapeutics Inc. (CIK: 0001919246) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTHS's EPS?
Pelthos Therapeutics Inc. has a diluted EPS of $-3.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PTHS's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pelthos Therapeutics Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PTHS stock overvalued or undervalued?
Valuation metrics for PTHS: ROE of -29.2% (sector avg: 15%), net margin of -93.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PTHS's AI grade for 2026?
Our dual AI analysis gives Pelthos Therapeutics Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTHS's free cash flow?
Pelthos Therapeutics Inc.'s operating cash flow is $-13.1M, with capital expenditures of $194.0K. FCF margin is -122.1%.
How does PTHS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -93.9% (avg: 12%), ROE -29.2% (avg: 15%), current ratio 2.79 (avg: 2).